An observational study in Schizophrenia, Metabolic Syndrome and Genetic Polymorphism, sponsored by Seoul National Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-12.
Sponsored by Seoul National Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Schizophrenia with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Korea, Republic of.
Among the 112 studies in Schizophrenia with a site in Korea, Republic of, this one is the 11th largest by planned enrollment of the 23 observational ones that give a count, is one of 11 that started in 2007, is one of 23 observational ones, and was the 26th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 112 studies in Schizophrenia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19–60
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 41 · Phase 4 27
First in 2002; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 291 across the 89 interventional studies, 100 across the 23 observational. Of the 92 that completed or were terminated, 47 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 112 have an industry lead sponsor. The 10 most frequent:
Seoul National Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Seoul National Hospital has 3 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Schizophrenia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07755605Samsung Medical CenterDigital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder | 2026-12 |
| NCT06821945Boryung Pharmaceutical Co., LtdA Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 112 studies in Schizophrenia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
The use of antipsychotics, especially clozapine and olanzapine is associated with metabolic side effects, which put patients with schizophrenia at risk for cardiovascular morbidity or diabetes.
The prevalence of the metabolic syndrome was 53.8% of patients who taking clozapine. The high interindividual variability in antipsychotic-induced metabolic abnormalities suggests that genetic makeup is a possible determinant.
The genotypes of the multiple gene such as HTR2C, LEP, adrenergic receptor,PPAR,GNB3 are suggested to have associations with the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome) in patients using antipsychotics.
We are going to investigate whether those multiple genetic polymorphisms are associated with the metabolic side effects in patients taking clozapine.
patients with schizophrenia taking clozapine more than 1 year
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* chronic schizophrenia * have been taking clozapine at leaset one year * without diabetes, pulmonary tuberculosis
The associations between multiplegenetic polymorphisms (HTR2C,leptin,adrenergic receptor,PPAR,GNB3) and the metabolic side effects (weight,glucose,lipid,BP,metabolic syndrome)
Time frame: more than 1 year after starting clozapine
The record gives a start of Oct 2007, a primary completion of Jan 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National Hospital